Previous studies have shown that adiponectin is a therapeutic target for obesity as higher serum concentrations of adiponectin protect against inflammation and are associated with a lower cardiovascular risk in obese subjects [27]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.